This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
by Zacks Equity Research
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca's Final Data From Key Lung Cancer Study Delayed
by Zacks Equity Research
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
by Zacks Equity Research
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
Get Rid of 5 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Overblown toxic stocks are generally susceptible to outside shocks and are loaded with a huge amount of debt.
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales
by Zacks Equity Research
Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.
Incyte (INCY) Beats on Sales in Q4
by Ekta Bagri
Incyte (INCY) beat on sales in the fourth quarter driven by growth in Jakafi sales.
Why Incyte (INCY) Might Surprise This Earnings Season
by Zacks Equity Research
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
by Zacks Equity Research
Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.
5 Biotech Stocks Set to Trump Estimates This Earnings Season
by Zacks Equity Research
Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.
AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018
by Zacks Equity Research
AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.
Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance
by Zacks Equity Research
Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.
Will Amgen (AMGN) Benefit From Growth Drugs in Q4 Earnings?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Merus' Antibody Candidate in Phase II Breast Cancer Study
by Zacks Equity Research
Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock
by Zacks Equity Research
Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock
Discard These 4 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Overblown toxic stocks are usually susceptible to outside shocks and loaded with a huge amount of debt.
Celgene to Acquire Impact Biomedicines to Boost Pipeline
by Zacks Equity Research
Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.
Zacks.com highlights: Covanta Holding, AMC Entertainment Holdings, Incyte, PTC and Cott
by Zacks Equity Research
Zacks.com highlights: Covanta Holding, AMC Entertainment Holdings, Incyte, PTC and Cott
Abandon These 5 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Toxic stocks are vulnerable to external shocks and are burdened with high levels of debt.
AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.
Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors
by Zacks Equity Research
Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors
Dispose of These 5 Toxic Stocks or Sell Short for Gains
by Zacks Equity Research
Toxic stocks are susceptible to outside shocks and are loaded with huge debt.